InvestorsHub Logo
Followers 195
Posts 687
Boards Moderated 0
Alias Born 10/27/2016

Re: None

Thursday, 08/26/2021 10:45:27 AM

Thursday, August 26, 2021 10:45:27 AM

Post# of 913
Cost containment is a big healthcare theme. ONS-5010 / LYTENAVA™ is part of the solution, in my view. Yes, it will cost more than off label bevacizumab but the majority of anti-vegf costs come from branded products, not off-label. So, overall, the introduction of LYTENAVA is cost containment positive.

I also think the OTLK is developing a pricing / reimbursement strategy that will pay docs more than what they receive with off-label bevacizumab.

As part of its pricing strategy, OTLK hired a consulting firm to survey insurance providers and determine price sensitivity. The results were very positive and indicate insurance providers will be very supportive with their reimbursement policies.

Last point, once a pre-filled syringe is available, the convenience benefit will make LYTENAVA compelling to the docs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLK News